Delaying anti-VEGF therapy during the COVID-19 pandemic: long-term impact on visual outcomes in patients with neovascular age-related macular degeneration

ObjectivesTo evaluate the outcomes of delayed intravitreal injections (IVIs) caused by the outbreak of coronavirus disease 2019 (COVID-19), in patients with neovascular age-related macular degeneration (nAMD).MethodsnAMD patients with scheduled IVIs between March 1(st) and April 30(th), 2020 were stratified through a risk-based selection into a non-adherent group (NA-group) if they skipped at least one IVI and an adherent group (A-group) if they followed their treatment schedule. During the pandemic visit (v(0)), if a significant worsening of the disease was detected, a rescue therapy of three-monthly IVIs was performed. Multimodal imaging and best-corrected visual acuity (BCVA) findings were evaluated after 6 months (v(6)), compared between groups and with the visit prior the lockdown (v(-1)).ResultsTwo hundred fifteen patients (132 females, mean age: 81.89 +/- 5.98 years) delayed their scheduled IVI while 83 (53 females, mean age: 77.92 +/- 6.06 years) adhered to their protocol. For both groups, BCVA at v(0) was significantly worse than v(-1) (mean 4.15 +/- 7.24 ETDRS letters reduction for the NA-group and 3 +/- 7.96 for the A-group) but remained stable at v(6). The two groups did not significantly differ in BCVA trends after 6 months and neither for development of atrophy nor fibrosis.ConclusionsA risk-based selection strategy and a rescue therapy may limit the long-term outcomes of an interruption of the treatment protocol in patients with nAMD.